[{"path":"index.html","id":"introduction","chapter":"1 Introduction","heading":"1 Introduction","text":"Predictive approaches assessing heterogeneity treatment effects (HTE) aim\ndevelopment models predicting either individualized effects \ntwo () treatments better individual [1]. \nprior work, divided methods three broader categories based \nreference class used defining patient similarity making individualized\npredictions recommendations [2]. First, risk-modeling approaches\nuse prediction baseline risk reference; second, treatment effect\nmodeling approaches also model treatment-covariate interactions, addition \nrisk factors; third, optimal treatment regime approaches focus developing\ntreatment assignment rules rely heavily modeling treatment effect\nmodifiers. key difference approaches parsimony \ndealing treatment effect modifiers, interaction considered (risk\nmodeling), limited number interactions (effect modeling), larger set\ninteractions (optimal treatment regime approaches).Risk-modeling approaches predictive HTE analyses provide viable option \nabsence well-established treatment effect modifiers [3,4]. simulations, modeling effect modifiers, .e.\ntreatment-covariate interactions, often led miscalibrated predictions \nabsolute benefit, risk-based methods proved quite robust terms \nbenefit calibration, although provided weaker discrimination benefit \npresence true effect modifiers [5]. often, risk-modeling\napproaches carried two steps: first risk prediction model \ndeveloped externally internally entire RCT population, “blinded” \ntreatment; RCT population stratified using prediction model \nevaluate risk-based treatment effect variation [6]. two-step\napproach identified substantial absolute treatment effect differences \nlow-risk high-risk patients re-analysis 32 large trials\n[7]. However, even though estimates risk subgroup level may \naccurate, estimates may need refinement individual patients,\nespecially patients predicted risk boundaries risk\nintervals. Hence, risk-stratified approach useful exploring \npresenting HTE, sufficient supporting treatment decisions \nindividual patients.individualize treatment effects, recent PATH statement suggested various\nrisk-based models including prognostic index baseline risk (PI) \ntreatment assignment [3,4]. current simulation study, \naim summarize compare different risk-based models predicting\nindividualized treatment effects. simulate different relations \nbaseline risk treatment effects also consider potential harms \ntreatment. illustrate different models case study predicting\nindividualized effects treatment acute myocardial infarction (MI) \nlarge randomized controlled trial (RCT).","code":""},{"path":"methods.html","id":"methods","chapter":"2 Methods","heading":"2 Methods","text":"","code":""},{"path":"methods.html","id":"background","chapter":"2 Methods","heading":"2.1 Background","text":"observe RCT data \\((Z, X, Y)\\), patient \\(Z_i= 0, 1\\) \ntreatment status, \\(Y_i = 0, 1\\) observed outcome \\(X_i\\) set \ncovariates measured. Let \\(\\{Y_i(z), z=0, 1\\}\\) denote unobservable potential\noutcomes. observe \\(Y_i = Z_iY_i(1) + (1 - Z_i)Y_i(0)\\). interested \npredicting conditional average treatment effect (CATE),\n\\[\\tau(x) = E\\{Y(0) - Y(1)|X=x\\}\\]\nAssuming \\((Z, X, Y)\\) random sample target population \n\\(\\big(Y(0), Y(1)\\big)\\perp \\!\\!\\! \\perp Z|X\\), RCT setting, can predict\nCATE \n\\[\\begin{align*}\n\\tau(x) &= E\\{Y(0)\\:\\vert\\:X=x\\}-E\\{Y(1)\\:\\vert\\:X=x\\}\\\\\n&=E\\{Y\\:\\vert\\:X=x, Z=0\\}-E\\{Y\\:\\vert\\:X=x, Z=1\\}\n\\end{align*}\\]Based estimate baseline risk\n\\[\nE\\{Y\\:\\vert\\:X=x, Z=0\\}=g\\big(lp(x)\\big)\n\\]\n\\(u=lp(x)=\\hat{\\beta}^tx\\) linear predictor \\(g\\) link function,\npredict CATE \n\\[\n\\hat{\\tau}(x) = g\\big(f(u, 0)\\big) - g\\big(f(u, 1)\\big)\n\\]\n\\(f(u,z)\\) describes interactions baseline risk linear predictor \ntreatment. rest paper use linear predictor \\(lp(x)\\) \nprognostic index (PI) outcome \\(Y\\).","code":""},{"path":"methods.html","id":"simulation-scenarios","chapter":"2 Methods","heading":"2.2 Simulation scenarios","text":"simulated typical RCT undertaken compare binary outcome\n(e.g. death) group patients treatment arm \ngroup untreated patients control arm. patient generated 8\nbaseline covariates \\(x_1,\\dots,x_4\\sim N(0, 1)\\) \\(x_5,\\dots,x_8\\sim B(1, 0.2)\\). Treatment allocated using 50:50 split. Outcomes patients \ncontrol arm generated logistic regression model including \nbaseline covariates. base scenarios coefficient values , \nAUC logistic regression model \\(0.75\\) event rate \ncontrol arm \\(20\\%\\). Binary outcomes control arm generated \nBernoulli variables true probabilities\n\\(P(y=1|X, t_x = 0) = \\text{expit}(PI)=\\frac{e^{PI}}{1+e^{PI}}\\).Outcomes treatment arm generated using 3 base scenarios: absent\ntreatment effect (= 1), moderate treatment effect (= 0.8) strong\ntreatment effect (= 0.5). started simulating outcomes based true\nconstant relative treatment effects 3 base scenarios. simulated\nlinear, quadratic non-monotonic deviations constant treatment effects\nusing:\n\\[lp_1 = \\gamma_2(PI-c)^2 + \\gamma_1(PI-c) + \\gamma_0, \\]\n\\(lp_1\\) true linear predictor treatment arm, \n\\(P(y=1|X, Z=1) = \\text{expit}(lp_1)\\). Finally, simulated scenarios \nconstant absolute harm applied across treated patients. case \n\\(P(y=1|X,Z=1) = \\text{expit}(lp_1) + \\text{harm}\\).sample size base scenarios set 4,250, since sample size\nprovides \\(80\\%\\) power detection marginal 0.8 \nstandard alpha 0.5%. evaluated effect smaller larger sample\nsizes 1,063 (4,250 divided 4) 17,000 (4250 multiplied 4),\nrespectively. also evaluated effect worse better discriminative\nability risk, adjusting baseline covariate coefficients, \nAUC regression model control arm 0.65 0.85 respectively.Combining settings resulted simulation study 648 scenarios\n(exact settings supplementary material). scenarios \nable cover observed treatment effect heterogeneity 32 large trials \nwell many potential variations risk-based treatment effect\n[7].","code":""},{"path":"methods.html","id":"individualized-risk-based-benefit-predictions","chapter":"2 Methods","heading":"2.3 Individualized risk-based benefit predictions","text":"risk-based methods assume risk prediction model available \nassign risk predictions individual patients. simulations developed\nprediction model internally entire population, using logistic\nregression model main effects baseline covariates treatment\nassignment. Baseline risk predictions individual patients derived \nsetting treatment assignment 0. Another common approach derive \nprediction model solely control patients, however approach \nshown lead biased benefit predictions [5,8,9].stratified HTE method suggested alternative traditional\nsubgroup analyses [3,4]. Patients stratified \nequally-sized risk strata—case based risk quartiles. Absolute\ntreatment effects within risk strata estimated difference event\nrate patients control arm patients treated arm. \nconsidered approach reference, expecting perform worse \ncandidates, objective provide illustration HTE rather\noptimize individualized benefit predictions.Second, considered model assumes constant relative treatment effect\n(constant odds ratio). Hence, absolute benefit predicted \n\\(\\hat{\\tau}(x) = \\text{expit}(PI) - \\text{expit}(PI +\\log(\\text{}))\\).Third, considered logistic regression model including treatment, \nprognostic index, linear interaction. Absolute benefit \nestimated \n\\(\\hat{\\tau}(x)=\\text{expit}(\\beta_0+\\beta_{PI}PI) - \\text{expit}(\\beta_0+\\beta_{t_x}+(\\beta_{PI}+\\beta_*)PI)\\).\nrefer method linear interaction approach.Fourth, used restricted cubic splines (RCS) relax linearity\nassumption effect linear predictor [10]. considered\nsplines 3 (RCS-3), 4 (RCS-4) 5 (RCS-5) knots compare models \ndifferent levels flexibility.Finally, considered adaptive approach using Akaike’s Information\nCriterion (AIC) model selection. specifically, adaptive\napproach ranked constant relative treatment effect model, linear\ninteraction model, RCS models 3, 4, 5 knots based AIC\nselected one lowest value. extra degrees freedom 1\n(linear interaction), 2, 3 4 (RCS models) increasingly complex\ninteractions treatment effect.","code":""},{"path":"methods.html","id":"evaluation-metrics","chapter":"2 Methods","heading":"2.4 Evaluation metrics","text":"evaluated predictive accuracy considered methods root mean\nsquared error (RMSE):\\[\\text{RMSE}=\\sqrt{\\frac{1}{n}\\sum_{=1}^n\\big(\\tau(x_i) - \\hat{\\tau}(x_i)\\big)^2}\\]\ncompared discriminative ability methods study using\nc--benefit [11]. c--benefit represents probability\ntwo randomly chosen matched patient pairs unequal observed\nbenefit, pair greater observed benefit also higher predicted\nbenefit. able calculate observed benefit, patients treatment\narm ranked based predicted benefit matched 1:1 across\ntreatment arms. Observed treatment benefit defined difference \nobserved outcomes untreated treated patient matched\npatient pair. Predicted benefit defined average predicted benefit\nwithin matched patient pair.evaluated calibration similar manner, using integrated calibration\nindex (ICI) benefit [12]. observed benefits regressed \npredicted benefits using locally weighted scatterplot smoother (loess).\nICI--benefit average absolute difference predicted \nsmooth observed benefit. Values closer \\(0\\) represent better calibration.scenario setting performed 500 replications, within \nconsidered models fitted. comparing models simulated \nsuper-population size 500,000 scenario. calculated RMSE \ndiscrimination calibration benefit models derived \nreplication simulation settings within super-population.","code":""},{"path":"methods.html","id":"empirical-illustration","chapter":"2 Methods","heading":"2.5 Empirical illustration","text":"demonstrated different methods individualizing treatment benefits\nusing data 30,510 patients acute myocardial infarction (MI)\nincluded GUSTO-trial.\n10,348\npatients randomized tissue plasminogen activator (tPA) treatment \n20,162\nrandomized streptokinase. outcome interest 30-day mortality\n(total 2,128 events), recorded patients.line previous analyses [13,14], fitted \nlogistic regression model 6 baseline covariates, .e. age, Killip class,\nsystolic blood pressure, heart rate, indicator previous MI, \nlocation MI, predict 30-day mortality risk. constant effect treatment\nincluded model. deriving risk predictions individuals set\ntreatment indicator 0. information model development can found\nsupplement (Supplement, Section 8).","code":""},{"path":"results.html","id":"results","chapter":"3 Results","heading":"3 Results","text":"","code":""},{"path":"results.html","id":"simulations","chapter":"3 Results","heading":"3.1 Simulations","text":"linear interaction model outperformed RCS methods terms RMSE \nscenarios true constant relative treatment effect (= 0.8, N = 4,250\nAUC = 0.75), strong linear even strong quadratic deviations \nconstant relative treatment effect (Figure ; panels\n-C). However, non-monotonic deviations constant relative treatment\neffect, RMSE linear interaction model increased substantially,\nespecially presence treatment-related harms (Figure\n; panel D). scenarios, RCS-3 outperformed \nmethods terms RMSE. might expected constant treatment effect\napproach overall best performance true constant treatment effect\nsettings. sensitive considered deviations, resulting increased\nRMSE. Finally, adaptive approach comparable performance \nbest-performing method scenario. However, comparison \nbest-performing approach, RMSE variable scenarios \nlinear non-monotonic deviations, especially also including moderate \nstrong treatment-related harms. closer inspection, found \nbehavior caused wrongly selecting constant\ntreatment effect model substantial proportion replications\n(Supplement, Figure S3). problematic behavior less larger sample\nsizes (see ).\nFigure 3.1: RMSE considered methods across 500 replications calculated simulated super-population size 500,000. scenario true constant relative treatment effect (panel ) true prediction AUC 0.75 sample size 4250. RMSE also presented strong linear (panel B), strong quadratic (panel C), non-monotonic (panel D) constant relative treatment effects. Panels right side present true relations baseline risk (x-axis) absolute treatment benefit (y-axis). 2.5, 25, 50, 75, 97.5 percentiles risk distribution expressed boxplot top. 2.5, 25, 50, 75, 97.5 percentiles true benefit distributions expressed boxplots side right-handside panel.\nIncreasing sample size 17,000 favored RCS-3 , achieved\nlowest close lowest RMSE across scenarios (Figure\n). Especially cases strong quadratic \nnon-monotonic deviations RCS-3 lower RMSE (median\n0.011\nstrong quadratic deviations \n0.010\nnon-monotonic deviations treatment-related harms) compared\nlinear interaction approach (median\n0.013 \n0.014,\nrespectively), regardless strength treatment-related\nharms. Due large sample size, RMSE adaptive approach\neven similar best-performing method, constant\nrelative treatment effect model less often wrongly selected\n(Supplement, Figure S4).\nFigure 3.2: RMSE considered methods across 500 replications calculated simulated samples size 17,000 rather 4,250 Figure . RMSE calculated super-population size 500,000\nincreased AUC true prediction model 0.85 (= 0.8 N =\n4,250). RCS-3 lowest RMSE case strong quadratic \nnon-monotonic deviations comparable performance – optimal –\nlinear interaction model case strong linear deviations (median RMSE\n0.016 RCS-3 compared \n0.014\nlinear interaction model). observed base case scenario \nadaptive approach wrongly selected constant treatment effect model\n(23%\n\n25%\nreplications strong linear non-monotonic deviation scenarios\nwithout treatment-related harms, respectively), leading variability \nRMSE (Supplement, Figure S5).\nFigure 3.3: RMSE considered methods across 500 replications calculated simulated samples 4,250. True prediction AUC 0.85. RMSE calculated super-population size 500,000\nassuming true constant relative treatment effect, discrimination \nbenefit slightly lower linear interaction model, \nsubstantially lower non-linear RCS approaches (Figure\n; panel ). strong linear quadratic deviations\nconstant relative treatment effect, methods discriminated quite\nsimilarly (Figure ; panels B-C). scenario \nnon-monotonic deviations, constant effect model much lower\ndiscriminative ability compared methods (median AUC \n0.4971\nconstant effects model,\n0.5285\nlinear interaction model \n0.5304\nbest-performing RCS-3; Figure ; panel D). \nadaptive approach unstable terms discrimination benefit,\nespecially presence treatment-related harms. increasing number \nRCS knots, observed decreasing median values increasing variability \nc--benefit scenarios. increased sample size 17,000\nobserved similar trends, however performance methods \nstable (Supplement, Figure S6). Finally, increased true prediction\nAUC 0.85 adaptive approach case non-monotonic deviations ,\n, conservative, especially null moderate treatment-related\nharms (Supplement, Figure S5).\nFigure 3.4: Discrimination benefit considered methods across 500 replications calculated simulated samples size 4,250. True prediction AUC 0.75.\nterms calibration benefit, constant effects model outperformed \nmodels scenario true constant treatment effects, \nmiscalibrated deviation scenarios (Figure ). \nlinear interaction model showed best close best calibration across \nscenarios showed worse calibration compared RCS-3 case \nnon-monotonic deviations treatment-related harms (Figure\n; panel D). adaptive approach worse calibrated \nscenarios strong linear non-monotonic deviations compared linear\ninteraction model RCS-3. increased sample size 17,000 similar\nconclusions calibration benefit drawn. expected, methods\ndisplayed stable calibration performance due larger number \npatients (Supplement, Figure S6). increased true prediction AUC \n0.85, linear interaction model worse calibrated, average, RCS-3\ncase strong quadratic deviations constant relative treatment\neffects (Supplement, Figure S7).results individual scenarios can explored online \nhttps://arekkas.shinyapps.io/simulation_viewer/. Additionally,\ncode simulations can found \nhttps://github.com/rekkasa/arekkas_HteSimulation_XXXX_2021\nFigure 3.5: Calibration benefit considered methods across 500 replications calculated simulated sample size 500,000. True prediction AUC 0.75 sample size 4,250.\n","code":""},{"path":"results.html","id":"empirical-illustration-1","chapter":"3 Results","heading":"3.2 Empirical illustration","text":"used derived prognostic index fit constant treatment effect model, \nlinear interaction model RCS-3 model individualizing absolute benefit\npredictions. RCS-4 RCS-5 models excluded. simulations \nmethods always outperformed simpler approaches often\noverfitted. Finally, adaptive approach 3 candidate models \nalso applied.considered methods provided similar fits, predicting increasing benefits \npatients higher baseline risk predictions. models followed \nevolution stratified estimates closely. adaptive approach based\nAIC selected constant treatment effect model. constant treatment\neffect model somewhat lower AIC compared linear interaction model\nslightly worse cross-validated discrimination (c--benefit\n0.525 vs\n0.526) better cross-validated\ncalibration (ICI-benefit 0.0104 vs\n0.0115). conclusion, simpler constant\ntreatment effect model adequate predicting absolute 30-day mortality\nbenefits treatment tPA patients acute MI.\nFigure 3.6: Individualized absolute benefit predictions based baseline risk using constant treatment effect approach, linear interaction approach RCS smoothing using 3 knots. Risk stratified estimates absolute benefit presented within quartiles baseline risk reference.\n","code":""},{"path":"discussion.html","id":"discussion","chapter":"4 Discussion","heading":"4 Discussion","text":"linear interaction model RCS-3 model displayed good\nperformance many considered simulation scenarios. linear\ninteraction model optimal cases smaller sample sizes moderately\nperforming baseline risk prediction models, , lower RMSE, \nbetter calibrated benefit better discrimination benefit, even \nscenarios strong quadratic deviations. scenarios true non-monotonic\ndeviations, linear interaction model outperformed RCS-3, especially\npresence true treatment-related harms. Increasing sample size \nprediction model’s discriminative ability favored RCS-3, especially \nscenarios non-monotonic deviations presence treatment-related\nharms.RCS-4 RCS-5 proved flexible considered scenarios, \nindicated higher RMSE, increased variability discrimination benefit\nworse calibration benefit predictions. Even larger sample sizes \nstrong quadratic non-monotonic deviations base case scenario \nconstant relative treatment effects, flexible restricted cubic\nsplines outperform simpler RCS-3. approaches may \nhelpful expect extreme patterns heterogeneous treatment effects\ncompared quadratic deviations considered . Considering interactions\nRCS-3 models complex approach often may reasonable.constant treatment effect model, despite adequate performance \npresence weak treatment effect heterogeneity relative scale, quickly\nbroke stronger deviations constant relative treatment effects. \ncases, stratified approach generally lower error rates compared \nconstant treatment effect model. stepwise treatment benefit estimates\nuseful visually demonstrating treatment effect heterogeneity may \nconsidered insufficient making individualized benefit predictions.Increasing discriminative ability risk model–increasing \npredictor coefficients true risk model–reduced RMSE methods. \nincrease discriminative ability translates higher variability predicted\nrisks, , turn, allows considered methods better capture absolute\ntreatment benefits. consequence, increase discriminative ability \nrisk model also led higher discrimination low high\nbenefit (reflected values c--benefit). Even though risk model\nperformance important ability risk-based methods predict\ntreatment benefit, prediction model development outside scope \nwork already studied extensively [5,8,9].adaptive approach adequate performance, following closely average \nperformance “true” model scenarios. smaller sample sizes \ntended miss treatment-risk interactions selected simpler models\n(Supplement Section 4). conservative behavior resulted increased RMSE\nvariability scenarios, especially case true strong linear \nnon-monotonic deviations base case scenario. Therefore, case \nsmaller sample sizes simpler linear interaction model may safer choice\npredicting absolute benefits presence suspected\ntreatment-related harms.limitation study assumed treatment benefit\nfunction baseline risk majority simulation\nscenarios. also considered constant moderate strong treatment-related\nharms, applied absolute scale expand range scenarios line\nprevious work [15]. limited set scenarios \nassumed existence true treatment-covariate interactions, conclusions\nremained unchanged. Even though average error rates increased \nconsidered methods, due miss-specification outcome model, \nlinear interaction model lowest error rates. RCS-3 comparable\nperformance. constant treatment effect model often gave biased results,\nespcially presence moderate strong treatment-related harms. \nresults simulations can found Supplement, Section 7. Future\nsimulation studies explore effect extensive deviations \nrisk-based treatment effects.simulations focused risk-based methods, using baseline risk \nreference two-stage approach individualizing benefit\npredictions. However, plethora different methods, ranging \ntreatment effect modeling tree-based approaches available recent\nliterature [16–19]. Many \nmethods rely incorporating treatment-covariate interactions prediction\nbenefit. important caveat approaches may prone \noverfitting, thus exaggerating magnitude predicted benefits. \nwide range simulation settings, simpler risk modeling approach \nconsistently better calibrated benefit compared complex treatment\neffect modelling approaches [5]. However, whether remains\ncase range empirical settings still needs explored Similarly,\nSYNTAX score II, model developed identifying patients complex\ncoronary artery disease benefit percutaneous coronary\nintervention coronary artery bypass grafting redeveloped using fewer\ntreatment-covariate interactions better external performance compared \npredecessor[20,21].conclusion, linear interaction approach viable option smaller\nsample sizes /moderately performing risk prediction models consider\nnon-constant relative treatment effect plausible. RCS-3 better option\nnon-monotonic deviations constant relative treatment effect /\nsubstantial treatment-related harms anticipated. Increasing complexity\nRCS models increasing number knots translate \nimproved benefit prediction. Using AIC model selection among constant\ntreatment effect, linear interaction RCS-3 model viable option,\nespecially larger sample size.","code":""},{"path":"references.html","id":"references","chapter":"5 References","heading":"5 References","text":"[1] Varadhan R, Segal JB, Boyd CM, Wu AW, Weiss CO. framework analysis heterogeneity treatment effect  patient-centered outcomes research. Journal Clinical Epidemiology 2013;66:818–25. https://doi.org/10.1016/j.jclinepi.2013.02.009.[2] Rekkas , Paulus JK, Raman G, Wong JB, Steyerberg EW, Rijnbeek PR, et al. Predictive approaches heterogeneous treatment effects: scoping review. BMC Medical Research Methodology 2020;20. https://doi.org/10.1186/s12874-020-01145-1.[3] Kent DM, Paulus JK, Klaveren D van, D’Agostino R, Goodman S, Hayward R, et al. predictive approaches treatment effect heterogeneity (PATH) statement. Annals Internal Medicine 2019;172:35. https://doi.org/10.7326/m18-3667.[4] Kent DM, Klaveren D van, Paulus JK, D’Agostino R, Goodman S, Hayward R, et al. predictive approaches treatment effect heterogeneity (PATH) statement: Explanation elaboration. Annals Internal Medicine 2019;172:W1. https://doi.org/10.7326/m18-3668.[5] Klaveren D van, Balan TA, Steyerberg EW, Kent DM. Models interactions overestimated heterogeneity treatment effects prone treatment mistargeting. Journal Clinical Epidemiology 2019;114:72–83. https://doi.org/10.1016/j.jclinepi.2019.05.029.[6] Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing reporting heterogeneity treatment effects clinical trials: proposal. Trials 2010;11. https://doi.org/10.1186/1745-6215-11-85.[7] Kent DM, Nelson J, Dahabreh IJ, Rothwell PM, Altman DG, Hayward RA. Risk treatment effect heterogeneity: Re-analysis individual participant data 32 large clinical trials. International Journal Epidemiology 2016:dyw118. https://doi.org/10.1093/ije/dyw118.[8] Burke JF, Hayward RA, Nelson JP, Kent DM. Using internally developed risk models assess heterogeneity treatment effects clinical trials. Circulation: Cardiovascular Quality Outcomes 2014;7:163–9. https://doi.org/10.1161/circoutcomes.113.000497.[9] Abadie , Chingos MM, West MR. Endogenous stratification randomized experiments. Review Economics Statistics 2018;100:567–80. https://doi.org/10.1162/rest_a_00732.[10] Harrell FE, Lee KL, Pollock BG. Regression models clinical studies: Determining relationships predictors response. JNCI Journal National Cancer Institute 1988;80:1198–202. https://doi.org/10.1093/jnci/80.15.1198.[11] Klaveren D van, Steyerberg EW, Serruys PW, Kent DM. proposed “concordance-statistic benefit” provided useful metric modeling heterogeneous treatment effects. Journal Clinical Epidemiology 2018;94:59–68. https://doi.org/10.1016/j.jclinepi.2017.10.021.[12] Austin PC, Steyerberg EW. integrated calibration index (ICI) related metrics quantifying calibration logistic regression models. Statistics Medicine 2019;38:4051–65. https://doi.org/10.1002/sim.8281.[13] Califf RM, Woodlief LH, Harrell FE, Lee KL, White HD, Guerci , et al. Selection thrombolytic therapy individual patients: Development clinical model. American Heart Journal 1997;133:630–9. https://doi.org/10.1016/s0002-8703(97)70164-9.[14] Steyerberg EW, Bossuyt PMM, Lee KL. Clinical trials acute myocardial infarction: adjust baseline characteristics? American Heart Journal 2000;139:745–51. https://doi.org/10.1016/s0002-8703(00)90001-2.[15] Glasziou PP, Irwig LM. evidence based approach individualising treatment. BMJ 1995;311:1356–9. https://doi.org/10.1136/bmj.311.7016.1356.[16] Athey S, Tibshirani J, Wager S. Generalized random forests. Annals Statistics 2019;47. https://doi.org/10.1214/18-aos1709.[17] Lu M, Sadiq S, Feaster DJ, Ishwaran H. Estimating individual treatment effect observational data using random forest methods. Journal Computational Graphical Statistics 2018;27:209–19. https://doi.org/10.1080/10618600.2017.1356325.[18] Wager S, Athey S. Estimation inference heterogeneous treatment effects using random forests. Journal American Statistical Association 2018;113:1228–42. https://doi.org/10.1080/01621459.2017.1319839.[19] Powers S, Qian J, Jung K, Schuler , Shah NH, Hastie T, et al. methods heterogeneous treatment effect estimation high dimensions. Statistics Medicine 2018;37:1767–87.[20] Farooq V, Van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo , et al. Anatomical clinical characteristics guide decision making coronary artery bypass surgery percutaneous coronary intervention individual patients: Development validation syntax score ii. Lancet 2013;381:639–50.[21] Takahashi K, Serruys PW, Fuster V, Farkouh , Spertus JA, Cohen DJ, et al. Redevelopment validation syntax score ii individualise decision making percutaneous surgical revascularisation patients complex coronary artery disease: Secondary analysis multicentre randomised controlled syntaxes trial external cohort validation. Lancet 2020;396:1399–412.","code":""}]
